Candriam Luxembourg S.C.A. raised its position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 38.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,400 shares of the biopharmaceutical company’s stock after acquiring an additional 28,400 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.34% of Loxo Oncology worth $9,433,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in shares of Loxo Oncology by 162.6% during the first quarter. Bank of America Corp DE now owns 8,176 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 5,063 shares during the period. Prudential Financial Inc. purchased a new stake in shares of Loxo Oncology during the second quarter valued at $5,415,000. Federated Investors Inc. PA boosted its stake in shares of Loxo Oncology by 21,561.6% during the second quarter. Federated Investors Inc. PA now owns 37,258 shares of the biopharmaceutical company’s stock valued at $2,988,000 after purchasing an additional 37,086 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Loxo Oncology by 4.6% during the second quarter. JPMorgan Chase & Co. now owns 54,800 shares of the biopharmaceutical company’s stock valued at $4,395,000 after purchasing an additional 2,400 shares during the period. Finally, Nicholas Investment Partners LP purchased a new stake in shares of Loxo Oncology during the second quarter valued at $5,036,000.

A number of analysts have recently issued reports on LOXO shares. BidaskClub lowered shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. JMP Securities lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $83.12 to $17.14 in a research note on Tuesday, August 29th. They noted that the move was a valuation call. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a research note on Thursday, September 28th. BTIG Research reaffirmed a “buy” rating and issued a $102.00 price objective (up from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $71.00 price objective on shares of Loxo Oncology in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $80.02.

Loxo Oncology, Inc. (LOXO) traded up $1.05 on Friday, hitting $81.18. 296,300 shares of the stock traded hands, compared to its average volume of 371,794. Loxo Oncology, Inc. has a 12-month low of $23.86 and a 12-month high of $95.92.

In other news, VP Jennifer Burstein sold 1,700 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $125,341.00. Following the transaction, the vice president now owns 1,700 shares in the company, valued at $125,341. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Avi Z. Naider sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $90.00, for a total transaction of $450,000.00. Following the transaction, the director now owns 154,118 shares in the company, valued at approximately $13,870,620. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,637 shares of company stock worth $8,670,337. Corporate insiders own 44.40% of the company’s stock.

WARNING: “Candriam Luxembourg S.C.A. Has $9.43 Million Holdings in Loxo Oncology, Inc. (LOXO)” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-has-9-43-million-holdings-in-loxo-oncology-inc-loxo/1698223.html.

Loxo Oncology Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.